Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.
Adolescent
Adult
Cardiovascular Diseases
/ complications
Child
Child, Preschool
Female
Hospitalization
/ statistics & numerical data
Humans
Incidence
Infant
Kidney Failure, Chronic
/ complications
Kidney Transplantation
/ statistics & numerical data
Male
Mortality
/ trends
Outcome Assessment, Health Care
Renal Dialysis
/ statistics & numerical data
Risk Factors
United States
/ epidemiology
Young Adult
Journal
JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
pubmed:
21
3
2019
medline:
6
2
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) is a leading cause of death among patients with end-stage renal disease (ESRD). Young adult (ages 22-29 years) have risks for ESRD-associated CVD that may vary from other ages. To test the hypothesis that young adult-onset ESRD is associated with higher cardiovascular (CV) hospitalizations and mortality with different characteristics than childhood-onset disease. This population-based cohort study used the US Renal Data System to categorize patients who initiated ESRD care between 2003 and 2013 by age at ESRD onset (1-11, 12-21, and 22-29 years). Cardiovascular hospitalizations were identified via International Classification of Diseases, Ninth Revision discharge codes and CV mortality from the Centers for Medicare & Medicaid ESRD Death Notification Form. Patients were censored at death from non-CVD events, loss to follow-up, recovery, or survival to December 31, 2014. Adjusted proportional hazard models (95% CI) were fit to determine risk of CV hospitalization and mortality by age group. Data analysis occurred from May 2016 and December 2017. Onset of ESRD. Cardiovascular mortality and hospitalization. A total of 33 156 patients aged 1 to 29 years were included in the study population. Young adults (aged 22-29 years) had a 1-year CV hospitalization rate of 138 (95% CI, 121-159) per 1000 patient-years. Young adults had a higher risk for CV hospitalization than children (aged 1-11 years; hazard ratio [HR], 0.41 [95% CI, 0.26-0.64]) and adolescents (aged 12-21 years; HR, 0.86 [95% CI, 0.77-0.97]). Of 4038 deaths in young adults, 1577 (39.1%) were owing to CVD. Five-year cumulative incidence of mortality in this group (7.3%) was higher than in younger patients (adolescents, 4.0%; children, 1.7%). Adjusted HRs for CV mortality were higher for young adults with all causes of ESRD than children (cystic, hereditary, and congenital conditions: HR, 0.22 [95% CI, 0.11-0.46]; P < .001; glomerulonephritis: HR, 0.21 [95% CI, 0.10-0.44]; P < .001; other conditions: HR, 0.33 [95% CI, 0.23-0.49]; P < .001). Adolescents had a lower risk for CV mortality than young adults for all causes of ESRD except glomerulonephritis (cystic, hereditary, and congenital conditions: HR, 0.45 [95% CI, 0.27-0.74]; glomerulonephritis: HR, 0.99 [95% CI, 0.76-1.11]; other: HR, 0.47 [95% CI, 0.40-0.57]). Higher risks for CV hospitalization and mortality were associated with lack of preemptive transplant compared with hemodialysis (hospital: HR, 14.24 [95% CI, 5.92-34.28]; mortality: HR, 13.64 [95% CI, 8.79-21.14]) and peritoneal dialysis [hospital: HR, 8.47 [95% CI, 3.50-20.53]; mortality: HR, 7.86 [95% CI, 4.96-12.45]). Nephrology care before ESRD was associated with lower risk for CV mortality (HR, 0.77 [95% CI, 0.70-0.85]). Cardiovascular disease accounted for nearly 40% of deaths in young adults with incident ESRD in this cohort. Identified risk factors may inform development of age-appropriate ESRD strategies to improve the CV health of this population.
Identifiants
pubmed: 30892557
pii: 2728081
doi: 10.1001/jamacardio.2019.0375
pmc: PMC6484951
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-362Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK007378
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK070869
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
J Am Soc Nephrol. 2014 Jun;25(6):1321-9
pubmed: 24652791
Am J Kidney Dis. 2018 May;71(5):648-656
pubmed: 29132947
J Pediatr. 2002 Aug;141(2):191-7
pubmed: 12183713
Am J Clin Nutr. 2004 Jul;80(1):193-8
pubmed: 15213048
Semin Dial. 2007 Nov-Dec;20(6):577-85
pubmed: 17991208
Am J Kidney Dis. 2012 Dec;60(6):1002-11
pubmed: 23022429
Natl Vital Stat Rep. 2016 Jun;65(4):1-122
pubmed: 27378572
N Engl J Med. 2004 Jun 24;350(26):2654-62
pubmed: 15215481
MMWR Recomm Rep. 2010 Sep 10;59(RR-9):1-15
pubmed: 20829749
J Am Soc Nephrol. 2017 May;28(5):1584-1591
pubmed: 28034898
Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9
pubmed: 9820470
Am J Transplant. 2011 Oct;11(10):2093-109
pubmed: 21883901
Stat Med. 1995 Mar 15-Apr 15;14(5-7):615-27
pubmed: 7792452
Am J Kidney Dis. 2017 Aug;70(2):281-289
pubmed: 28143671
Am J Kidney Dis. 2017 Mar;69(3 Suppl 1):A7-A8
pubmed: 28236831
Stat Med. 1997 Apr 30;16(8):901-10
pubmed: 9160487
Stat Methods Med Res. 2013 Dec;22(6):661-70
pubmed: 22072596
N Engl J Med. 2019 Jan 10;380(2):142-151
pubmed: 30586318
J Am Soc Nephrol. 2016 Feb;27(2):551-8
pubmed: 26054540
Nephrol Dial Transplant. 2005 Nov;20(11):2420-6
pubmed: 16115854
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
Clin Kidney J. 2015 Dec;8(6):772-80
pubmed: 26613038
Crit Care Med. 2016 Aug;44(8):1530-7
pubmed: 26985636
Am J Kidney Dis. 2015 Jul;66(1 Suppl 1):Svii, S1-305
pubmed: 26111994
Am J Kidney Dis. 2001 Nov;38(5):992-1000
pubmed: 11684552
Blood Purif. 2011;31(1-3):203-8
pubmed: 21228591
Kidney Int. 2016 Aug;90(2):389-395
pubmed: 27157696
Pediatr Nephrol. 2017 Dec;32(12):2319-2330
pubmed: 28762101
Pediatr Nephrol. 2005 Jul;20(7):849-53
pubmed: 15834618
J Am Soc Nephrol. 2019 Feb;30(2):201-215
pubmed: 30655312
Nephrol Dial Transplant. 2010 Apr;25(4):1025-32
pubmed: 20019018
Kidney Int. 2003 Mar;63(3):793-808
pubmed: 12631061